While Novo Nordisk’s stock has taken a hit ... even as it navigates the competitive landscape and patent expiration challenges. Disclaimer & Disclosure Report an Issue ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the Danish drugmaker.

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline ... experimental obesity drugs have hit the stock hard. Shares have lost nearly 60% since ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline ... experimental obesity drugs have hit the stock hard. Shares have lost nearly 60% since ...